Journal: Translational Lung Cancer Research
Article Title: Nanoassemblies loaded with low-dose paclitaxel can enhance the response of lung cancer immunotherapy by activating dendritic cells
doi: 10.21037/tlcr-2025-180
Figure Lengend Snippet: Antitumor mechanism analysis. (A) HE staining of tumor tissues. Scale bar =100 μm. (B) The apoptosis induction as determined by TUNEL assay. Scale bar =50 μm. (C) The number of CD4 + and (D) CD8 + T cells in tumors detected by IHC. Scale bar =50 μm. (E) The distribution of CD8 + T cells in tumors detected by IHC. Scale bar =100 μm. (F-H) Tumor cell apoptosis and the abundance of CD4 + T cells and CD8 + T cells were assessed by counting the rate of TUNEL-positive cells and the number of CD4 + and CD8 + T cells, respectively. *, P<0.05; **, P<0.01; ***, P<0.001; ns, no significance. FA NA, folic acid-modified nanoassemblies; FA-PTX NA, folic acid-modified nanoassemblies loaded with paclitaxel; HE, hematoxylin and eosin; IHC, immunohistochemistry; NS, normal saline; PD-1, programmed cell death protein-1; TUNEL, terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick end labeling.
Article Snippet: The cell suspensions were then stained with fluorochrome-labeled antibody-targeting murine CD4-FITC (eBioscience, San Diego, CA, USA), CD8-APC (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA), or an appropriate isotype control antibody and then analyzed by flow cytometry (Beckman Coulter, Brea, CA, USA).
Techniques: Staining, TUNEL Assay, Modification, Immunohistochemistry, Saline, End Labeling